Vaxart stock price forecast the most recent Vaxart stock price

The most recent Vaxart stock price forecast aligns with biotech peer performance. Comparable microcaps in the sector rallied 15% on breakthrough news in April, hinting at upside potential if VXRT delivers trial milestones. Although the valuation of a company is important, it ideally won't be the sole piece of analysis you scrutinize for a company. It's not possible to obtain a foolproof valuation with a DCF model. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. For Vaxart, we've compiled three additional factors you should further research: According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral. Vaxart’s near-term price forecast is clouded by earnings date speculation, with historical patterns showing post-report spikes averaging 9%. This aligns with broader biotech volatility indexes trending higher in Q